ACS Medicinal Chemistry Letters
Page 12 of 13
[9]Muñoz, M. F.; Puebla, M.; Figuero, X. F. Control of the
[25] Fantacuzzi, M.;Maccallini, C.; Di Matteo, M.;Ammazzalorso,
neurovascular coupling by nitric oxide-dependent regulation of
astrocytic Ca2+ signalling. Front. Cell. Neurosci. 2015, 10, 9–59.
[10] Fahey J. M., Girotti A. W. Nitric Oxide Antagonism to Anti-
Glioblastoma Photodynamic Therapy: Mitigation by Inhibitors of
Nitric Oxide Generation. Cancers 2019, 11, 231.
[11] Stojković, S.; Podolski-Renić, A.; Dinić, J.; Stanković, T.;
Banković, J.; Hadžić, S.; Paunovi, V.; Isaković, A.; Tanić, N.; Pešić,
M. Development of resistance to antiglioma agents in rat C6 cells
caused collateral sensitivity to doxorubicin. Experimental Cell
Research 2015, 335, 248-257.
[12] Dave, B., Gonzalez, D. D.; Liu, Z; Li, X.; Wong, H.; Granados,
S.; Ezzedine, N. E.; Sieglaff, D. H.; Ensor, J. E.; Miller, K. D.;
Radovich, M; Etrovic, A. K.; Gross, S. S.; Elemento, O.; Mills, G. B.;
Gilcrease, M. Z.; Chang, J. C. Role of RPL39 in Metaplastic Breast
Cancer. J Natl Cancer Inst 2017, 109.
[13] Godoy, L. C.; Anderson, C. T. M.; Chowdhury, R.; Trudel, L.
J.; Wogan, G. N. NO supports chemoresistance in melanoma. PNAS
2012, 109, 20373-20378
A.; Bruno, I.; De Filippis, B.; Giampietro, L.; Mollica, A.; Amoroso,
R. Screening of NOS activity and selectivity of newly synthesized
acetamidines using RP-HPLC. Journal of Pharmaceutical and
Biomedical Analysis 2016, 120, 419-424.
[26]Maccallini, C.; Di Matteo, M.; Gallorini, M.; Montagnani, M.;
Graziani, V.; Ammazzalorso, A.; Amoia, P.; De Filippis, B.; Di
Silvestre, S.; Fantacuzzi, M.; Giampietro, L.; Potenza, M.A.; Re, N.;
Pandolfi, A.; Cataldi, A.; Amoroso, R. Discovery of N-{3-
[(ethanimidoylamino)methyl]benzyl}-l-prolinamidedihydrochloride:
A new potent and selective inhibitor of the inducible nitric oxide
synthase as a promising agent for the therapy of malignant glioma. Eur.
J. Med. Chem. 2018, 25, 53-64.
[27] Eyler, C. E.; Wu,Q.; Yan, K.; MacSwords, J. M.; Chandler-
Militello,D.; Misuraca, K. L.; Lathia, J. D.; Forrester, M. T.; Lee, J.;
Stamler, J. S.; Goldman, S. A.; Bredel, M.; McLendon, R. E.; Sloan,
A. E.; Hjelmeland, A. B.; Rich, J. N. Glioma Stem Cell Proliferation
and Tumor Growth Are Promoted by Nitric Oxide Synthase-2. Cell,
2011, 146, 53–66
[28] Rebello, S.S.; Zhu, B.; McMonagle-Strucko, K.; Pulicicchio,
C.; Merrill, J.; Luo, Y.; Shen, L.; Wang, J.; Adler, D.; Natarajan, C.
Pharmacokinetic and pharmacodynamic evaluation of inhibitors of
inducible nitric oxide synthase (iNOS) in mice. AAPS PharmSci,
002237.pdf
[29] Gallorini, M.; Maccallini, C.; Ammazzalorso, A.; Amoia, P.;
De Filippis, B.; Fantacuzzi, M.; Giampietro, L.; Cataldi, A.; Amoroso,
R. The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces
Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.
Int. J. Mol. Sci. 2019, 20, 495.
[30] Ueda, S.; Terauchi,H.; Kawasaki, M.; Yano, A.; Ido, M.
Structure–Activity Relationships of 2-Aminothiazole Derivatives as
Inducible Nitric Oxide Synthase Inhibitor. Chem. Pharm. Bull. 2004,
52, 634-637.
[31] Turan-Zitouni, G.; Altıntop, M. D.; Özdemir, A.; Kaplancıklı,
Z. A.; Çiftçi, G. A.; Temel, H. E. Synthesis and evaluation of bis-
thiazole derivatives as new anticancer agents. Eur. J. Med. Chem.
2016,107, 288-294.
[32] Finiuk, N. A.; Klyuchivska, O.; Ivasechko, I.; Hreniukh, V.;
Ostapiuk, Y.; Shalai, Y.; Panchuk, R.; Matiychuk, V.; Obushak, M.;
Stoika, R.; Babsky, A. Proapoptotic effects of novel thiazole derivative
on human glioma cells. Anti-Cancer Drugs 2019, 30, 27-37.
[33] Maccallini, C.; Patruno, A.; Besker, N.; Ali, J. I.;
Ammazzalorso, A.; De Filippis, B.; Franceschelli, S.; Giampietro, L.;
Pesce, M.; Reale, M.; Tricca, M. L.; Re, N.; Felaco, M.; Amoroso, R.
Synthesis, biological evaluation, and docking studies of N-substituted
acetamidines as selective inhibitors of inducible nitric oxide synthase.
J. Med. Chem. 2009, 52, 1481−1485.
[34] Maccallini, C.; Di Matteo, M.; Ammazzalorso, A.; D'Angelo,
A.; De Filippis, B.; Di Silvestre, S.; Fantacuzzi, M.; Giampietro, L.;
Pandolfi, A.; Amoroso, R. Reversed-phase high-performance liquid
chromatography method with fluorescence detection to screen nitric
oxide synthases inhibitors. J. Sep. Sci. 2014, 37,1380-1385.
[35] Sun, W.; Zhang, W.; Yu, J.; Lu, Z.; Yu, J. Inhibition of Nrf2
might enhance the anti-tumor effect of temozolomide in glioma cells
via inhibition of Ras/Raf/MEK signaling pathway. Int J Neurosci.
2020,1‐16.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[14] Kaliyaperumal, K.; Sharma, A. K.; McDonald, D. G.; Dhindsa,
J. S.; Yount, C.; Singh, A. K.; Won, J. S.; Singh, I. S-
Nitrosoglutathione-mediated
STAT3 regulation in efficacy of
radiotherapy and cisplatin therapy in head and neck squamous cell
carcinoma. Redox Biol. 2015, 6, 41-50.
[15] Kielbik, M.; Szulc-Kielbik, I.; Klink, M. The Potential Role of
iNOS in Ovarian Cancer Progression and Chemoresistance. Int. J. Mol.
Sci. 2019, 20, 1751.
[16] Hallinan, E. Ann; Tjoeng, Foe S.; Fok, Kam F.; Hagen, Timothy
J.; Toth, Mihaly V.; Tsymbalov, Sofya; Pitzele, Barnett S.(G.D. Searle
and Co.) Preparation of N6-(1-iminoethyl)-L-lysine derivatives useful
as nitric oxide synthase inhibitors. US 6143790 A 20001107, 2000
[17] Hansen, Donald W., Jr.; Hallinan, E. Ann; Hagen, Timothy J.;
Kramer, Steven W.; Metz, Suzanne; Peterson, Karen B.; Spangler, Dale
P.; Toth, Mihaly V.; Fok, Kam F.; Bergmanis, Arija A.; Webber, R.
Keith; Trivedi, Mahima; Tjoeng, Foe S.; Pitzele, Barnett S. Preparation
of cyclic amidino agents useful as nitric oxide synthase inhibitors. US
6011028 A 20000104, 2000.
[18] Hallinan, Ann E.; Hansen, Donald W., Jr.; Tsymbalov, Sofya
Preparation of N-tetrazolyl amino acid amides and related compounds
as nitric oxide synthase inhibitors. US 5854251 A 19981229, 1998
[19] Strub, A.; Wolf-Rüdiger,H.; Eltze, C.; Fuchss, M.; Strassner,
T.; Strand, S.; Lehner, M. D.; Rainer, B. The novel imidazopyridine
2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-
imidazo[4,5-b]pyridine
(BYK191023) is a highly selective inhibitor of the inducible nitric-
oxide synthase. Mol.Pharmacol. 2006 ,69. 328-337.
[20] Minhas, R.; Bansal, Y.; Bansal, G. Inducible nitric oxide
synthase inhibitors: A comprehensive update. Med.Res. Rev. 2020, 40,
823-855.
[21] Maccallini, C.; Gallorini, M.; Cataldi, A.; Amoroso, R.
Targeting iNOS As a Valuable Strategy for the Therapy of Glioma
ChemMedChem 2020, 15, 339–344.
[22] Garvey, E.P.; Oplinger, J.A.;Furfine, E.S.; Kiff, R.J.; Laszlo,
F.; Whittle, B. J.; Knowles, R. G. 1400W is a slow, tight binding, and
highly selective inhibitor of inducible nitric-oxide synthase in vitro and
in vivo. J Biol Chem. 1997, 272, 4959‐4963.
[23]Maccallini, C.; Di Matteo, M.; Vullo, D.; Ammazzalorso, A.;
Carradori, S.; De Filippis, B.; Fantacuzzi, M.; Giampietro, L.; Pandolfi,
A.; Supuran, C.T.; Amoroso, R. Indazole, Pyrazole, and
OxazoleDerivatives Targeting Nitric Oxide Synthases and
CarbonicAnhydrases. ChemMedChem 2016, 1695-1699.
[24] Maccallini, C.; Montagnani, M.; Paciotti, R.; Ammazzalorso,
A.; De Filippis, B.; Di Matteo, M.; Di Silvestre, S.; Fantacuzzi, M.;
Giampietro, L.; Potenza, M. A.; Re, N.; Pandolfi, A.; Amoroso, R.
[36] Yu, D.; Liu, Y.; Zhou, Y.; Ruiz-Rodado, V.;Larion, M.; Xu, G.;
Yang, C..Triptolide suppresses IDH1-mutated malignancy via Nrf2-
driven glutathione metabolism. Proc Natl AcadSci U S A. 2020,117,
9964‐9972.
Selective acetamidine-based
nitric oxide synthase inhibitors:
synthesis, docking, and biological studies. ACS Med. Chem. Lett. 2015,
6, 635−640.
ACS Paragon Plus Environment